Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

William Bowling

Physician Assistant Texarkana, TX Physician Assistant

NPI 1053560979 CMS profile 10873622

5002 Cowhorn Creek Rd, Texarkana, TX 75503

Open in the dashboard

General payments

$9,127

596 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Bowling of Texarkana, TX is reported in the CMS Open Payments database as having received $9,127 across 596 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,957 114
2024 General $1,891 112
2023 General $1,905 136
2022 General $1,817 128
2021 General $1,557 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Bowling
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to William Bowling were reported at $1,957. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year William Bowling Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,557 $132 $37–$438 $132
2022 $1,817 $155 $48–$522 $149
2023 $1,905 $167 $52–$557 $160
2024 $1,891 $178 $55–$600 $164
2025 $1,957 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,557 125 payments
  2. AstraZeneca Pharmaceuticals LP $1,470 73 payments
  3. Lilly USA, LLC $1,195 84 payments
  4. Pfizer Inc. $705 52 payments
  5. GlaxoSmithKline, LLC. $672 56 payments
  6. Amgen Inc. $475 33 payments
  7. Novo Nordisk Inc $408 25 payments
  8. Merck Sharp & Dohme Corporation $242 16 payments
  9. Janssen Pharmaceuticals, Inc $237 15 payments
  10. Mylan Specialty L.P. $211 12 payments
  11. Other $1,955 105 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,115 595 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. BREZTRI $744 29 payments
  2. QULIPTA $741 63 payments
  3. FARXIGA $693 41 payments
  4. MOUNJARO $599 43 payments
  5. UBRELVY $589 52 payments
  6. TRELEGY ELLIPTA $508 45 payments
  7. ELIQUIS $501 44 payments
  8. NURTEC ODT $423 35 payments
  9. ZEPBOUND $421 26 payments
  10. VRAYLAR $419 34 payments
  11. Other $7,067 430 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

6,537

Median for Physician Assistant: 241

Drug cost

$409,708

Median for Physician Assistant: $4,110

Branded share of claims

12.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 100 $112,670
Eliquis Apixaban Brand 61 $59,789
Jardiance Empagliflozin Brand 53 $42,593
Farxiga Dapagliflozin Propanediol Brand 48 $39,984
Ozempic Semaglutide Brand 43 $37,896
Januvia Sitagliptin Phosphate Brand 12 $11,483
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 13 $11,127
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 16 $10,306
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $10,220
Trulicity Dulaglutide Brand 11 $9,414

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$109,321

Of which drugs: $13,103

Medicare patients

440

Average age 75

Services billed

4,716

246 women, 194 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 38%
Diabetes 30%
Ischemic heart disease 25%
Chronic kidney disease 25%
COPD 17%
Depression 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 59 60 $4,870
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 152 $102
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 48 420 $31
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 44 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $184
$184 48 —
ZEPBOUND
  • Lilly USA, LLC $159
$159 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $147
$147 16 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $116
$116 — —
VRAYLAR
  • AbbVie, Inc. $104
$104 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

596 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record